their mutation-specificity excludes up to 85% of KRAS-mutant cancers, including those with G12D, G12V, and G13D mutations. To address this gap, we developed RV-1521, a broad-spectrum mRNA vaccine ...

The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene is mutated in over 90% of pancreatic adenocarcinoma (PDAC). These mutations are predominantly single-base missense variants, 98% of which are ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein ...

Cancer vaccines have been a tantalizing idea for ... The company’s lead candidate, ELI-002, targets KRAS mutations, found in some 25% of all solid tumors including 88% of pancreatic ductal ...

They will also work on an inhibitor of KRAS G12C that could compete with sotorasib (BI 1823911) and an MEK inhibitor (BI 3011441), as well as a novel undisclosed bi-specific TRAILR2 agonist.

With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent. Recent FDA approvals of KRAS G12C inhibitors have ...

Targeted 7therapies and Anti-PD-(L)1 Therapies have emerged as vital treatment options, yet KRAS mutations, especially KRAS G12C, have been historically difficult to address. Due to the unique ...

Due to the inefficiency of target therapy such as anti-EGFR inhibitors, CRC patients with KRAS mutation eagerly require more effective therapies Methods We performed a combined transcriptomic sequence ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company ...

KRAS mutations drive approximately 25% of human cancers, with KRAS G12D being the most prevalent and challenging to target. Recent advances have led to developing small molecule inhibitors that ...